The estimated Net Worth of Myron Z Holubiak is at least $2.72 Million dollars as of 27 September 2019. Mr Holubiak owns over 558,597 units of Citius Pharmaceuticals Inc stock worth over $1,055,889 and over the last 20 years he sold CTXR stock worth over $188,355. In addition, he makes $1,475,625 as Pres und CEO & Director at Citius Pharmaceuticals Inc.
Mr has made over 13 trades of the Citius Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 558,597 units of CTXR stock worth $502,737 on 27 September 2019.
The largest trade he's ever made was buying 784,314 units of Citius Pharmaceuticals Inc stock on 13 August 2018 worth over $1,003,922. On average, Mr trades about 37,652 units every 102 days since 2005. As of 27 September 2019 he still owns at least 1,992,243 units of Citius Pharmaceuticals Inc stock.
You can see the complete history of Mr Holubiak stock trades at the bottom of the page.
Myron Z. Holubiak is the Pres, CEO & Director at Citius Pharmaceuticals Inc.
As the Pres und CEO & Director of Citius Pharmaceuticals Inc, the total compensation of Mr Holubiak at Citius Pharmaceuticals Inc is $1,475,625. There are no executives at Citius Pharmaceuticals Inc getting paid more.
Mr Holubiak is 74, he's been the Pres und CEO & Director of Citius Pharmaceuticals Inc since . There are 3 older and 9 younger executives at Citius Pharmaceuticals Inc. The oldest executive at Citius Pharmaceuticals Inc is Suren Dutia, 77, who is the Independent Director.
Myron's mailing address filed with the SEC is C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ, 07016.
Over the last 9 years, insiders at Citius Pharmaceuticals Inc have traded over $0 worth of Citius Pharmaceuticals Inc stock and bought 13,825,289 units worth $15,819,221 . The most active insiders traders include Leonard L Mazur, Myron Z Holubiak und Dennis M Mcgrath. On average, Citius Pharmaceuticals Inc executives and independent directors trade stock every 207 days with the average trade being worth of $523,934. The most recent stock trade was executed by Eugene Myron Holuka on 13 March 2024, trading 2,415 units of CTXR stock currently worth $48.
citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.
Citius Pharmaceuticals Inc executives and other stock owners filed with the SEC include: